In contrast, the anti-PD-1 (programmed cell death-1)/PD-L1 (programmed cell death ligand-1) immunotherapy has become standard therapy for NSCLC patients without oncogenic driver mutations [6–8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.